The Third Way? Von Eschenbach Promotes Behind-The-Counter Drug Class
Executive Summary
FDA and industry should immediately begin pursuing the development of a regulatory process for a behind-the-counter class of drugs, FDA Commissioner Andrew von Eschenbach told the Consumer Healthcare Product Association's annual executive conference